Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P.

Haematologica. 2014 May;99(5):922-9. doi: 10.3324/haematol.2013.093161. Epub 2014 Jan 31.

2.

Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation.

Brodsky A, Mazzocchi O, Sánchez F, Khursigara G, Malhotra S, Volpacchio M.

Exp Hematol Oncol. 2012 Sep 6;1(1):26. doi: 10.1186/2162-3619-1-26.

3.

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M.

Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12.

PMID:
21222185
4.

Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure.

Kelly RJ, Hill A, Arnold LM, Khursigara G, Kanagasundaram NS, Hillmen P.

Leuk Res. 2011 Apr;35(4):560-2. doi: 10.1016/j.leukres.2010.10.021. Epub 2010 Dec 8. No abstract available.

PMID:
21145109
5.

Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W.

Am J Hematol. 2010 Aug;85(8):553-9. doi: 10.1002/ajh.21757. Erratum in: Am J Hematol. 2010 Nov;85(11):911.

6.

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W.

N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060. No abstract available.

PMID:
20445192
7.

The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab.

Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, Loughney A, Beauchamp J, Khursigara G, Rother RP, Chalmers E, Fyfe A, Fitzsimons E, Nakamura R, Gaya A, Risitano AM, Schubert J, Norfolk D, Simpson N, Hillmen P.

Br J Haematol. 2010 May;149(3):446-50. doi: 10.1111/j.1365-2141.2010.08099.x. Epub 2010 Feb 11.

PMID:
20151973
8.

A prosurvival function for the p75 receptor death domain mediated via the caspase recruitment domain receptor-interacting protein 2.

Khursigara G, Bertin J, Yano H, Moffett H, DiStefano PS, Chao MV.

J Neurosci. 2001 Aug 15;21(16):5854-63.

9.

The uniqueness of being a neurotrophin receptor.

Lee FS, Kim AH, Khursigara G, Chao MV.

Curr Opin Neurobiol. 2001 Jun;11(3):281-6.

PMID:
11399425
10.

Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.

Kim AH, Khursigara G, Sun X, Franke TF, Chao MV.

Mol Cell Biol. 2001 Feb;21(3):893-901.

11.

p75 neurotrophin receptor as a modulator of survival and death decisions.

Casaccia-Bonnefil P, Gu C, Khursigara G, Chao MV.

Microsc Res Tech. 1999 May 15-Jun 1;45(4-5):217-24. Review.

PMID:
10383114
12.

Association of the p75 neurotrophin receptor with TRAF6.

Khursigara G, Orlinick JR, Chao MV.

J Biol Chem. 1999 Jan 29;274(5):2597-600.

13.

Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome.

Bell SA, Du Clos TW, Khursigara G, Picazo JJ, Rubin RL.

J Autoimmun. 1995 Apr;8(2):293-303.

PMID:
7542004
14.

Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils.

Jiang X, Khursigara G, Rubin RL.

Science. 1994 Nov 4;266(5186):810-3.

PMID:
7973636

Supplemental Content

Loading ...
Support Center